Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Amylin Pharmaceuticals LLC    AMLN   US0323461089

News SummaryMost relevantAll newsSector news 

Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Webcast First Quarter Results

04/19/2012 | 04:20pm US/Eastern

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first quarter of 2012 on Thursday, April 26, 2012 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date pre-market, Amylin will release financial results for the first quarter of 2012.

The call will be webcast live through the "Investors" section of Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to approximately 15 minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (888) 989-4344 (U.S./Canada) or (312) 470-7140 (international), participant passcode number 7994841. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (800) 756-0205 (U.S./Canada) or (203) 369-3002 (international).

About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin is committed to delivering novel therapies that transform the way diabetes and other metabolic disorders are treated. Amylin is headquartered in San Diego, Calif. and has a commercial manufacturing facility in Ohio. More information on Amylin Pharmaceuticals is available at

Amylin Pharmaceuticals, Inc.
Christine Everett-Zedelmayer
Alice Izzo

© Business Wire 2012
React to this article
2012 AMYLIN PHARMACEUTICALS, INC. : Bristol-Myers Squibb and AstraZeneca Complete Exp..
2012DJEli Lilly To Record $1.26 Billion Benefit from Amylin
2012DJASTRAZENECA : Bristol-Myers Squibb Completes Purchase of Amylin
2012DJBristol-Myers Executive Charged With Insider Trading
2012DJBristol-Myers Executive Charged With Insider Trading
2012DJBristol-Myers Executive Charged With Insider Trading
2012 Bristol-Myers executive charged with insider trading
2012DJU.S. Charges Bristol-Myers Executive With Insider Trading
2012DJBristol-Myers Pension Executive Robert Ramnarine Arrested for Alleged Insider..
2012DJEvercore 2nd-Quarter Profit Climbs 19% On Higher Investment Banking Revenue
Duration : Period :
Amylin Pharmaceuticals LLC Technical Analysis Chart | AMLN | US0323461089 | 4-Traders